DPP4 and COVID-19: Moreover, by retrieving information on exposure to DPP‐4 inhibitors among patients with diabetes hospitalized for COVID‐19 at an outbreak hospital in Italy, Fadini et al found no evidence that DPP‐4 inhibitors may be more useful for infected patients with diabetes.27